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Abstract: Next-generation sequencing (NGS) technologies have led to an increase in the diagnosis
of heterogeneous genetic conditions. However, over 50% of patients with a genetically inherited
disease are still without a diagnosis. In these cases, different hypotheses are usually postulated,
including variants in novel genes or elusive mutations. Although the impact of copy number
variants (CNVs) in neuromuscular disorders has been largely ignored to date, missed CNVs are
predicted to have a major role in disease causation as some very large genes, such as the dystrophin
gene, have prone-to-deletion regions. Since muscle tissues express several large disease genes,
the presence of elusive CNVs needs to be comprehensively assessed following an accurate and
systematic approach. In this multicenter cohort study, we analyzed 234 undiagnosed myopathy
patients using a custom array comparative genomic hybridization (CGH) that covers all muscle
disease genes at high resolution. Twenty-two patients (9.4%) showed non-polymorphic CNVs.
In 12 patients (5.1%), the identified CNVs were considered responsible for the observed phenotype.
An additional ten patients (4.3%) presented candidate CNVs not yet proven to be causative. Our study
indicates that deletions and duplications may account for 5–9% of genetically unsolved patients.
This strongly suggests that other mechanisms of disease are yet to be discovered.
Keywords: copy number variants; skeletal muscle disorders; next-generation sequencing; variants of
uncertain significance
1. Introduction
Prior to the advent of next-generation sequencing (NGS), high phenotypic overlapping and lack
of pathognomonic signs in neuromuscular disorders (NMDs) made clinical diagnosis difficult and
molecular confirmation extremely complex and challenging [1]. In the NGS era, different genetic
approaches have been described in literature [2,3] with a detection rate of single nucleotide variants or
small ins/dels ranging between 40% and 60% [4].
Patients remaining undiagnosed may harbor mutations in unknown genes, multifactorial or
polygenic conditions, or elusive variants such as deep intronic mutations, variants in regulatory
elements, trinucleotide repeat expansions and copy number variants (CNVs) [5].
CNVs are defined as genomic deletions and duplications of 50 base pairs (bp) or longer [6] that
may account for 5–10% of elusive mutations in the human genome [7]. To date, few custom array
comparative genomic hybridization (CGH) studies on muscular genes have been described [8–10].
Recently, CNVs were detected from target sequencing, whole exome, or genome data by applying
different computational algorithms [11,12]. Despite the use of bioinformatics tools, array CGH remains
the gold standard for detection of exon CNVs [13].
Previous reports suggested that the frequency of CNVs in myopathy patients is around 4–10% [9].
However, these studies mainly provided a technical validation of array CGH platforms [8,9],
with a limited number of genes [10] and/or patients tested [9]. In this study, we enrolled
234 patients who had remained undiagnosed after an extensive molecular investigation including
Sanger sequencing of candidate genes and MotorPlex, a targeted NGS panel designed to detect
single-base substitutions or small ins/dels [14].
We analyzed these genetically undiagnosed patients by Motor Chip, a custom array CGH for the
detection of deletions and duplications in 425 neuromuscular genes [9], and identified causative and
potential disease-causing CNVs in 22 patients.
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2. Materials and Methods
2.1. Patients Recruited
We collected DNA samples from 504 patients presenting with clinical signs of limb-girdle
muscular dystrophies, congenital myopathies and other conditions affecting the muscles including
isolated hyperCKemia. All samples were analyzed by a targeted NGS tool, named MotorPlex [14,15],
to identify single nucleotide changes as well as small ins/dels. Based on DNA availability, 234 out
of 286 myopathic patients who had remained undiagnosed after this preliminary NGS study were
recruited to look for CNVs. The patients involved in the project GUP11006 had already provided
written informed consent at the time of blood collection and the Ethics Committee of the University of
Campania, Naples, Italy approved the extension of the project [14]. Genomic DNA from leukocytes of
peripheral blood was isolated using standard operating procedures established by the EuroBioBank
network. DNA quality and quantity were assessed using spectrophotometric (Nanodrop ND
1000, Thermo Scientific Inc., Rockford, IL, USA) and fluorometry-based (Qubit 2.0 Fluorometer,
Life Technologies, Carlsbad, CA, USA) methods.
2.2. Array CGH and Pair Analysis
All the undiagnosed patients were enrolled for this study immediately after analysis of NGS
results in 2015. At that time, few bioinformatics tools were available for CNV analysis on whole exome
data, but none had been optimized for use on data from targeted NGS. We used the most user-friendly
tool, SureCall (Agilent Technologies, Santa Clara, CA, USA) and tested its ability to identify CNVs
from 50 targeted NGS samples. The SureCall algorithm uses pair analysis (sample vs. reference),
comparing the per base read depth coverage of each target interval for sample and reference BAM files.
Aberration intervals were predicted by the log2 ratio of depth coverage of the sample to the reference.
A custom array CGH named Motor Chip, able to investigate more than 400 genes related
to neuromuscular disorders with an exonic resolution, was then used for the detection and
characterization of CNVs [9]. Labeling and hybridization were performed using SureTag labeling
kit (Agilent Technologies) according to the manufacturer’s specifications. Scanned array images
were analyzed by Cytogenomics v4 (Agilent Technologies). After performing a quality control
test, duplications and deletions were identified using the Aberration Detection Method 2 (ADM-2)
algorithm. At least three target probes with changes in the number of copies were required for a CNV
call. Deletions and duplications corresponding to well-known copy number polymorphisms were
filtered off [16]. Variants not known to be pathogenic or of doubtful significance were compared
with the Database of Genomic Variants [17], DECIPHER (https://decipher.sanger.ac.uk/), and ExAC
Browser (http://exac.broadinstitute.org/) to facilitate their interpretation. Data reported here are
submitting to ClinVar [18] and Leiden [19].
2.3. Validation Experiments
2.3.1. Real-Time PCR
All identified CNVs were further confirmed by real-time PCR using the Bio-Rad CFX96 system
(Bio-Rad, Pleasanton, CA, USA). Specific primers (available from the authors on request) able to
investigate the deleted or duplicated regions were designed using the Primer 3 webtool. The 20 µL
reaction contained 10 µL 2X FastStart universal SYBR Green Master (Bio-Rad), 10 µM of each primer,
and 10 ng of genomic DNA as template. The following thermal conditions were used: 10 min of
preheating at 95 ◦C followed by 45 cycles of 15 s at 95 ◦C, 30 s at 62 ◦C and an extension of 68 ◦C for
30 s. Quantitative analysis was performed by CFX Manager (Bio-Rad). The identified variants are
reported based on the following coding DNA reference sequence, as suggested by the Human Genome
Variation Society (HGVS) recommendations: DMD (NM_004006.2), LAMA2 (NM_000426.3), SGCD
(NM_000337.5), SGCB (NM_000232.4), SGCG (NM_000231.2), SPAST (NM_014946.3).
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2.3.2. MLPA Analysis for DMD and SPAST Genes
Complete or partial deletions/duplications involving DMD and SPAST genes were confirmed
by Multiplex ligation-dependent probe amplification (MLPA) using the SALSA MLPA P034 and
P035 DMD kits and P165 SPAST kit (MRC-Holland, Amsterdam, The Netherlands), according to the
manufacturer’s recommendations. MLPA data analysis was performed with the Coffalyser.net package
(MRC-Holland).
2.3.3. cDNA Analysis
To further characterize the duplications, a detailed analysis of the transcript was conducted.
RNA was isolated from leukocytes of peripheral blood or from muscular biopsies, according to
standard procedures. A specific coding sequence demonstrating the predicted tandem duplications
was then amplified and bidirectionally sequenced on an ABI 3130xL automatic DNA sequencer
(Applied Biosystems, Foster City, CA, USA).
2.3.4. Histological Studies and Western Blot Analysis
Histological and histochemical examinations in muscle biopsies were carried out following
standard procedures [20]. Western blotting of muscle biopsy samples was performed according to
standard methods [21].
3. Results
After NGS analysis, 50 undiagnosed patients were initially tested for CNVs by SureCall pair
analysis, which confidently identified on average eight CNV calls per sample. Motor Chip, performed
to validate the identified CNVs, showed that SureCall pair analysis achieved a detection rate of about
40–60%. Because of the high number of CNV calls with low sensitivity and the lack of accuracy in CNV
breakpoint mapping -with the SureCall pair analysis, we used Motor Chip to further test the remaining
undiagnosed patients. Motor Chip analysis identified a causative deletion or duplication in genes
responsible for the observed phenotype in 12 out of 234 patients (5.1%) (Figure 1). Molecular findings
and clinical data of patients carrying the identified CNVs are summarized in Table 1.
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2 deletions and 2 duplications in LAMA2 (patients V–VIII); (c) 3 deletions involving sarcoglycan genes (patients IX–XI); (d) SPAST gene deletion in patient XII. 
Green bars indicate deletions and red bars indicate duplications. The results of genomic quantification by real-time PCR are schematically represented (bottom of 
c). The number of each coding exon along gene is surmounted by a square corresponding to the number of detected copies. 
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Table 1. Causative copy number variants.
ID Onset SymptomsReferred
Muscle Weakness
(Distribution) Serum CK EMG Biopsy Findings Other Gene Allele 1 Allele 2
Reading
Frame
I childhood muscleweakness lower limbs >20X myopathic dystrophic features
RF:2950 mL
(75%) DMD
hem del: exons
45–51 (mat) - in frame
II childhood muscleweakness lower limbs >20X myopathic dystrophic features n.a. DMD
hem del: exons
45–49 (U) - in frame
III - hyperCKemia asymptomatic >20X n.a. myopathic features RF:2550 mL(92%) DMD
het del: exons
45–48 (pat) - in frame
IV adult muscleweakness lower limbs >20X n.a. dystrophic features
RF:2720 mL
(104%) DMD
het del: exons
3–7 (de novo) -
out of
frame
V juvenile epilepsy mild scapula winging,no muscle weakness >20X n.a.
dystrophic features with
partial merosin deficiency
(both 80 and 300 kD)
n.a. LAMA2 dup: exons21–55 (pat)
c.5374G>T, p.
Glu1792*
(ex 37) (mat)
in frame
VI congenital psychomotordelay normal normal n.a. n.a. autism LAMA2
del: exons 13–37
(pat)
c.6599G>A, p.
Arg2200His
(ex 47) (mat)
in frame
VII juvenile distalweakness
slight bilateral scapula
winging, positive
Gowers sign, mild
waddling gait, slight
atrophy of the right
more than left
upper > lower limbs
6–10X myopathic n.a. mild pectusexcavatum LAMA2
del: exons 13–14
(mat)
c.4312-1G>A p.?
(ex 29) (pat)
out of
frame
VIII juvenile difficulties inwalking lower limbs >10X n.a. n.a.
RF:2400 mL
(72%) LAMA2
dup: exons 4–12
(pat)
c.6429+3A>C, p.
Iso2144Glnfs7*
(ex 45) (mat)
in frame
IX juvenile muscleweakness
proximal, lower >
upper limbs >20X myopathic dystrophic features
RF:2720 mL
(78%) SGCD
del: first coding
exon (pat)
del: first coding
exon (mat) in frame
X juvenile muscleweakness proximal >20X myopathic dystrophic features n.a. SGCB
del: last 12
codons in exon 6
and 3’ UTR (U)
del: last 12
codons in exon 6
and 3′ UTR (U)
in frame
XI childhood difficulties inwalking proximal four limbs >20X n.a. dystrophic features
RF:3380 mL (67%)
and dilated
cardiomyopathy
SGCG del: exon 7 (mat)
c.124_126delTTC
p. Leu41del
(ex2) (pat)
out of
frame
XII juvenile hyposthenia,fatigue
proximal in the lower
limbs normal mixed n.a. n.a. SPAST del: exons 10–16 - in frame
Abbreviations: n.a. = not available, CK = creatine kinase, EMG = electromyography, RF = respiratory function, mat = maternal, pat = paternal, U = unknown, het = heterozygous;
hem = hemizygous, UTR = untranslated region.
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4. Causative CNVs
4.1. CNVs in Dystrophin Gene
Previously, described dystrophin gene (DMD-MIM 300377) deletions [22] were identified in four
patients (two men and two women) presenting with proximal weakness and/or isolated serum CK
levels 10 times over the maximum normal range (patients I–IV). The deletion of exons 3–7 in patient
IV occurred de novo. In patient III the deletion of exons 45–48 was inherited from her affected father,
who had remained undiagnosed due to a very mild phenotype and a very low increase in CK values.
4.2. CNVs in Laminin-2 Gene
In four patients, laminin-2 gene (LAMA2-MIM 156224) CNVs were detected in the presence of
a previously identified heterozygous single nucleotide mutation by MotorPlex. In particular, patient
V carried an unreported nonsense mutation (c.5374G>T, p. Glu1792*) and a 190.6 kb intragenic
duplication. A further molecular characterization of the LAMA2 transcript, isolated from leukocytes,
showed a tandem, in-frame duplication involving exons 21–55 of the gene (Figure 2a,b). A merosin
deficiency was confirmed by Western blotting of skeletal muscle. Patient VI harbored a previously
unreported missense variant in exon 47 of LAMA2 gene (c.6599G>A, p.Arg2200His) and a known
heterozygous in-frame deletion of exons 13–37 [9] in the same gene. Array CGH identified a novel
heterozygous LAMA2 deletion (exons 13–14) generating a frameshift of open reading frame in patient
VII, affected by a congenital myopathy. In the same patient, MotorPlex had identified a heterozygous
mutation affecting the canonical splice site (c.4312-1G>A) of exon 29.
Similarly, patient VIII harbored a previously undescribed intronic variant (c.6429+3A>C) as well
as a 75 kb intragenic duplication (exons 4–12). Muscular RNA analysis identified two transcripts
(Figure 2c,d): one transcript with skipping of exons 44 and 45 leading to the loss of reading frame
(due to the intronic splicing variant) and a second transcript showing an in-frame duplication of
1386 nucleotides, predicted to produce a protein longer by 462 amino acids. However, we were unable
to perform a Western bot analysis as additional tissue was not available.
4.3. CNVs in Sarcoglycan Genes
In patient IX, we found a previously unreported homozygous deletion of the first coding exon
of δ-sarcoglycan gene (SGCD-MIM 601411). His unaffected parents were heterozygous for the
observed CNV. Similarly, the strong clinical suspicion for patient X and the lack of a causative variant
after NGS analysis prompted us to check the coverage for sarcoglycan genes. NGS data coverage
showed the absence of reads in the last exon of beta-sarcoglycan gene (SGCB-MIM 600900) suggesting
a deletion. Motor Chip analysis defined the deletion at the last 12 codons in exon 6 and the 3’ UTR
(untranslated region) [23]. We also detected a reported heterozygous deletion spanning exon 7 of
gamma-sarcoglycan gene (SGCG-MIM 608896) on the maternal allele of patient XI [24]. In the same
patient, NGS analysis had previously identified an in-frame 3 nucleotide deletion (c.124_126del), listed
in the LOVD database [19], on the father’s allele in exon 2 of SGCG gene.
4.4. Deletion in Spastin Gene
We found a reported in-frame heterozygous deletion of exons 10–16 [25] of spastin gene
(SPAST-MIM 604277) in patient XII, who presented with fatigue and hyposthenia since adolescence.
A large segregation analysis showed the presence of the deletion in her three affected relatives (III-1,
III-8, IV-3; Supplementary Figure S1) and in her asymptomatic sister (III-7; Supplementary Figure S1).
Three unaffected family members (III-3, III-4, III-6; Supplementary Figure S1) were negative for the
observed deletion, while genetic testing was not performed in the clinically affected patients II-3 and
IV-1, who refused DNA investigations.
We identified variants of uncertain significance (VUS) in ten patients (4.3%) (Table 2). VUS are
genomic variants not previously reported in normal individuals and with insufficient information
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about their clinical significance [26]. As required by the American College of Medical Genetics and
Genomics guidelines, an exhaustive characterization will be needed to clarify their clinical meaning.
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Table 2. Variants of uncertain significance.
ID Onset SymptomsReferred
Muscle Weakness
(Distribution) Serum CK EMG Biopsy Findings Other
CNV (Min Interval)
hg19 Description
Reading
Frame
XIII adult difficulties inwalking lower limbs 6X n.a. n.a.
RF:4330 mL (124%)
and atrial septum
defect
chr19:51857476-51871484 het del: ETFBexons 1–2 n.a.
XIV juvenile
shoulder and
pelvic girdle
weakness
severe proximal muscle
weakness, wheelchair
bound
3X myopathic dystrophic features mild respiratoryinsufficiency chr16:83342046-83949780
het del: CDH13,
HSBP1 and
MLYCD
n.a.
XV juvenile proximalweakness
weakness in posterior
muscles and quadriceps
and distal in lower limbs
N/10X myopathic aspecific, internal nuclei slight cardiachypertrophy chr10:69898720-69909802
het del: MYPN
exons 3–5 out of frame
XVI young adult limb-girdleweakness proximal and axial 15X n.a.
dystrophic features,
neurogenic and
myofibrillar damage,
partial αDG reduction
dilated
cardiomyopathy chr11:18536283-19213867
het del: CSRP3
exons 4–7 and
3′UTR
n.a.
XVII congenital congenitalarthrogryposis none N n.a. fiber type dystroportion - chr15:22756504-23088787
dup: TUBGCP5,
CYFIP1, NIPA2
and NIPA1
n.a.
XVIII juvenile distal weakness proximal and distal N myopathic
dystrophic features,
central nuclei, increased
connectival tissue and
rare vacuoles
- chr15:44862731-44900870 het del: SPG11exons 18–32 in frame
XIX childhood skin problem proximal and distal, notwalking n.a. n.a. n.a. - chrX:18910408-30489847 het del: 34 genes* n.a.
XX adult hyperCKemia proximal 7X normal myopathic features - chr17:41050890-41053142 het del: G6PCexon 1 (pat) n.a.
XXI young adult lower limb distalweakness
distal involvement, with
steppage, mild-to
moderate weakness of
trapezius and iliopsoas,
mild bulbar involvement,
minima facial weakness
N mixed core myopathy, desminaccumulation
atrial fibrillation and
flutter, bilateral atrial
dilatation, right
branch block
chr1:26140297-26140584 dup: SEPN1 exons11–12 n.a.
XXII juvenile muscle weakness n.a. 15X n.a. core myopathy - chr1:164682483-168354339 het del: 21 genes * n.a.
Abbreviations: n.a. = not available, CK = creatine kinase, EMG = electromyography, RF = respiratory function, pat = paternal, DG = dystroglycan, N = normal, het = heterozygous;
del = deletion; dup = duplication. * list of genes is available upon request.
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5. Discussion
5.1. Role of CNVs in Skeletal Muscle Disorders
Whole exome and targeted sequencing have proven to be robust and cost-efficient diagnostic
tools in heterogeneous diseases, increasing the detection rate of disease-causing variants compared to
the traditional gene-by-gene approach [28]. However, over 50% of undiagnosed patients affected by
nonspecific skeletal muscle disorders do not receive any molecular diagnosis using NGS strategies [14].
Taking advantage of a large cohort of myopathy patients previously screened with a gene
panel assay, we designed a study aiming to verify the presence of CNVs in unsolved patients [14].
An extensive screening of 234 myopathy patients by Motor Chip identified 22 CNVs. A causative
deletion or duplication was found in 12 out of the 234 patients (5.1%).
The identification of deletions or duplications in DMD gene causing Becker muscular dystrophy
(BMD) was not unexpected, and only confirmed the clinical overlap between BMD and limb-girdle
muscular dystrophy [29]. In total, 2.2% of the original 504 patients recruited to the study were
diagnosed with BMD, including those carrying the 7 single nucleotide variants (small indels, nonsense
and splice site variants) identified by MotorPlex [14].
The presence of female carriers as isolated cases in the absence of affected males in the family
(case IV) is noteworthy. The diagnosis of a Duchenne muscular dystrophy or BMD manifesting carrier
should be suspected in a female presenting with limb-girdle weakness, despite a negative family
history [30]. As previously reported for X-Linked myotubular myopathy [31,32], the extensive use of
genome-wide tools in a diagnostic setting will identify an increasing number of BMD manifesting
carriers, probably due to skewed X-chromosome inactivation [33]. Their identification will be crucial
for appropriate genetic counseling and correct prenatal diagnosis.
Several LAMA2 intragenic deletions and duplications were previously reported [34]. In our cohort,
we found a CNV in four out of 15 patients (27%) harboring a rare (minor allele frequency < 1%) single
nucleotide variant in LAMA2. Interestingly, LAMA2 CNVs in compound heterozygosity with a protein
truncating variant (PTV) were observed in three patients. Therefore, in the presence of a heterozygous
PTV, a CNV affecting the second allele should always be suspected.
CNVs in sarcoglycan genes are generally considered a rare event. However, our results, as well
as previous data [9], suggest that their incidence has likely been underestimated. As in the case of
LAMA2, screening for exonic deletions/duplications in sarcoglycan genes is strongly recommended in
patients carrying a single heterozygous mutation, above all if a reduction of sarcoglycan proteins is
observed [23].
Deletions in SPAST gene are common in hereditary spastic paraplegia [35]. However, the high
phenotypic variability of the disease makes clinical evaluation and molecular characterization
challenging, especially when proximal muscle weakness in the limbs and minimal neurological
signs are present [36], as in patient XII. In this case, identification of the SPAST deletion provided the
molecular diagnosis in her family, increasing the number of described cases. As previously reported,
the presence of an asymptomatic carrier of a spastin deletion may be considered a reduced penetrance
of the disorder [36].
Retrospectively, we performed a SureCall analysis using 10 out of 12 causative CNVs as positive
controls. Although in four samples (II, VI, VIII, IX) we identified the respective deletion or duplication
previously found with array CGH, breakpoints were not correctly defined. Unlike MotorPlex,
which provides exon level coverage, Motor Chip design comprises probes covering the intronic
region of neuromuscular genes, yielding a better definition of CNV breakpoints.
5.2. Variants of Uncertain Significance
We identified non-recurrent rare CNVs, which we interpreted as VUS, in ten patients (4.3%)
including heterozygous deletions involving genes responsible for autosomal recessive muscle disorders
(ETFB-patient XIII; MLYCD-patient XIV). Despite our exhaustive genetic investigation, including an
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NGS strategy and a CNV assessment, the presence of further elusive variants (such as deep intronic
variants or small repeat changes) in these genes cannot be excluded.
Two interesting heterozygous deletions were found in genes (MYPN-patient XV and
CSRP3-patient XVI) associated with a dominant cardiomyopathy. Specifically, an MYPN deletion
was found in patient XV presenting with hypertrophic cardiomyopathy and centronuclear myopathy.
Biallelic mutations of MYPN are associated with a slowly progressive nemaline myopathy [37] and
a recessive cap myopathy [38]. However, no other single nucleotide variants in MYPN were identified
in this patient. Still more complex is the interpretation of the CSRP3 deletion identified in patient XVI,
who presented with dilated cardiomyopathy and muscle weakness. To date, no CSRP3 mutations
have been associated with a skeletal muscle phenotype. However, no other variants in myopathy
disease genes included in our Motor Chip and MotorPlex panels explain the observed phenotype
in these two cases. Although MYPN and CSRP3 may have a role in the observed cardiomyopathies,
the primary genetic cause of the skeletal muscle disorder in these patients remains to be identified.
A duplication of the 15q11.2 region was found in patient XVII affected by congenital
arthrogryposis. The patient recently obtained a clinical diagnosis of Nail Patella syndrome, confirmed
by the identification of a de novo variant in LMX1B gene. However, the role of the identified duplication
is still unclear since CNVs in the 15q11.2 region are normally associated with neurodevelopmental
disorders [39,40].
Segregation studies in only two cases, patient XVIII and patient XIX excluded the primary disease
role of a heterozygous deletion of SPG11 gene and Xp22.13-p22.12, respectively.
In contrast, the G6PC deletion detected in patient XX and the SEPN1 duplication found in patient
XXI are not sufficient to explain the observed clinical phenotype in the absence of comprehensive
biochemical and molecular evidence. Lastly, a heterozygous deletion of 1q23.3-24.2 was identified in
patient XXII presenting with core myopathy. As this rearrangement involves five disease genes not
previously associated with core myopathy, its role remains unclear.
In sum, although these VUS may not act as primary disease drivers, we cannot exclude the
possibility that some may play a role as modifiers, contributing to the observed phenotype. However,
the absence of functional assays and the lack of comparisons with similar cases are a limitation in the
clinical interpretation of these rearrangements.
6. Conclusions
Here, we report the results observed in the largest cohort of patients with a skeletal muscle
disorder analyzed to date by array CGH. In line with data reported in literature, our findings confirm
that deletions and duplications are present in 5–9% of patients affected by a skeletal muscle disorder
without a molecular diagnosis. However, further extensive studies will be needed to clarify the role
of CNVs in about half of these cases. The addition of data (including frequency) on CNVs to the
ExAC database may assist in the clinical interpretation of observed rearrangements [41]. However, as
evidenced here as well as by others, the integration of NGS results with biochemical, histological and
Western blotting findings remains crucial for a correct clinical and diagnostic evaluation [23,42].
Although NGS panels are extensively applied in clinical settings for the detection of single
nucleotide variants or small ins/dels, identification of deletions or duplications of whole exons,
particularly single-exon CNVs, has proved problematic [43].Improvements to tools identifying CNVs
from NGS data are regularly reported [11,12]. Since several algorithms used to detect CNVs from NGS
data [11] are now available, the exclusive adoption of SureCall for the identification of CNVs from
NGS data may represent a limitation of this study. We are aware that more advanced algorithms may
likely have higher sensitivity and specificity. However, their use still generates a high number of false
positives, and their readouts still require validation by other methods such as array CGH or MLPA for
further mapping of breakpoints. Array CGH remains the gold standard method for CNV detection
and analysis, especially in diagnostics, as it is a well-established and validated strategy. Noteworthy,
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our study suggests that Sanger sequencing is still the only reliable method for determining exact
breakpoints at base-pair level, especially for duplications.
Since muscle tissues express several very large disease genes, some of which are prone to deletions
or duplications, further assessment of possible CNVs is strongly advised in neuromuscular diagnostic
settings. Finally, the use of whole genome sequencing or single-molecule long-read sequencing will
help extend the search to other elusive variants not detectable by targeted or whole exome sequencing
and CNV mapping [44].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/9/11/524/s1,
Figure S1: Pedigree of family with the SPAST deletion. Female III-5 in the pedigree corresponds to patient XII,
harboring deletion of exons 10–16 of SPAST gene.
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